A Novel Missense Mutation of the MEN1 Gene in a Patient with Multiple Endocrine Neoplasia Type 1 with Glucagonoma and Obesity

Intern Med. 2015;54(19):2475-81. doi: 10.2169/internalmedicine.54.4886. Epub 2015 Oct 1.

Abstract

A 35-year-old obese diabetic man presented with recurrent primary hyperparathyroidism during a three-year outpatient follow-up. He was clinically diagnosed with multiple endocrine neoplasia type 1 (MEN1) due to the presence of a pituitary adenoma and multiple glucagonomas. The glucagonomas may have affected his glycemic control. However, he did not demonstrate weight loss, suggesting that the patient's obesity could have obscured the early diagnosis of a glucagonoma. Genetic testing revealed a novel missense mutation at codon 561 in exon 10, resulting in an amino acid substitution from methionine to arginine (M561R) in the MEN1 gene. This mutation appeared to be responsible for the MEN1 pathogenicity.

Publication types

  • Case Reports

MeSH terms

  • Adult
  • Amino Acid Substitution
  • DNA Mutational Analysis
  • Diabetes Mellitus, Type 2
  • Genetic Testing
  • Glucagonoma / diagnosis*
  • Glucagonoma / genetics
  • Glucagonoma / surgery
  • Humans
  • Hyperparathyroidism, Primary / diagnosis*
  • Hyperparathyroidism, Primary / etiology
  • Hyperparathyroidism, Primary / genetics
  • Male
  • Multiple Endocrine Neoplasia Type 1 / diagnosis*
  • Multiple Endocrine Neoplasia Type 1 / genetics
  • Multiple Endocrine Neoplasia Type 1 / surgery
  • Mutation, Missense / genetics*
  • Obesity / complications
  • Pancreatic Neoplasms / diagnosis*
  • Pancreatic Neoplasms / genetics
  • Pancreatic Neoplasms / surgery
  • Proto-Oncogene Proteins

Substances

  • MEN1 protein, human
  • Proto-Oncogene Proteins